Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 3/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183904 | 1.00 | LPL (0.42) | LPLLIPGANPEPLAP3JAK2 | |
| SCHEMBL31156286 | 0.84 | JAK2 (0.40) | LPLLIPGJAK2BTKAAK1 | |
| SCHEMBL16637594 | 0.84 | LPL (0.38) | LPLLIPGJAK2BTKAAK1 | |
| SCHEMBL4232484 | 0.83 | LPL (0.43) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL31301038 | 0.83 | LPL (0.43) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL29680508 | 0.82 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL29036359 | 0.82 | LPL (0.37) | LPLLIPGANPEPLAP3 | |
| SCHEMBL29080160 | 0.82 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL17618242 | 0.81 | LPL (0.42) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL29486902 | 0.80 | LPL (0.41) | LPLLIPGANPEPLAP3P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-114702495-A | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| CN-108473495-B | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | LPL 4301/4885LIPG 3180/4885ANPEP 3521/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | LPL 4301/4885LIPG 3180/4885ANPEP 3521/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | LPL 3608/4885LIPG 1590/4885ANPEP 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.